Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

219

Participants

Timeline

Start Date

February 13, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions
Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Interventions
DRUG

JS203 for Injection

"2-steps:JS203 for Injection is administered on the first and eighth day of the first cycle and every 3 weeks thereafter.~3-steps:JS203 for Injection is administered on the first, eighth and fifteenth day of the first cycle and every 3 weeks thereafter.~4-steps:JS203 for Injection is administered on the first, eighth, fifteenth and twenty-second day of the first cycle and every 3 weeks thereafter."

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER